[go: up one dir, main page]

TW200509911A - Novel combination - Google Patents

Novel combination

Info

Publication number
TW200509911A
TW200509911A TW093122923A TW93122923A TW200509911A TW 200509911 A TW200509911 A TW 200509911A TW 093122923 A TW093122923 A TW 093122923A TW 93122923 A TW93122923 A TW 93122923A TW 200509911 A TW200509911 A TW 200509911A
Authority
TW
Taiwan
Prior art keywords
novel combination
ace
activator
inhibitor
combinations
Prior art date
Application number
TW093122923A
Other languages
Chinese (zh)
Inventor
David Nathan Abraham Fox
Eric Howard Karran
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TW200509911A publication Critical patent/TW200509911A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Combinations comprising (a) an activator of soluble guanylate cyclase and (b) an inhibitor of angiotensin enzyme (ACE) are useful for treating hypertension.
TW093122923A 2003-08-01 2004-07-30 Novel combination TW200509911A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0318094.0A GB0318094D0 (en) 2003-08-01 2003-08-01 Novel combination

Publications (1)

Publication Number Publication Date
TW200509911A true TW200509911A (en) 2005-03-16

Family

ID=27799666

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093122923A TW200509911A (en) 2003-08-01 2004-07-30 Novel combination

Country Status (3)

Country Link
GB (1) GB0318094D0 (en)
TW (1) TW200509911A (en)
WO (1) WO2005011727A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005031575A1 (en) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Use of soluble guanylate cyclase activators to promote wound healing
WO2008124505A2 (en) * 2007-04-05 2008-10-16 Ironwood Pharmaceuticals,Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
EP2585055A1 (en) * 2010-06-25 2013-05-01 Bayer Intellectual Property GmbH Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
SG10201700454PA (en) * 2012-07-20 2017-03-30 Bayer Pharma AG Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
ES2700989T3 (en) 2012-12-21 2019-02-20 Mayo Found Medical Education & Res Methods and materials to treat calcified aortic valve stenosis
US10028973B2 (en) 2014-09-22 2018-07-24 Mayo Foundation For Medical Education And Research Using DNA methyltransferase inhibitors to treat calcific aorta valve disease
WO2019055859A1 (en) * 2017-09-14 2019-03-21 Ironwood Pharmaceuticals, Inc. Treatment of metabolic syndrome with an sgc stimulator
SG11202110533RA (en) 2019-04-10 2021-10-28 Mayo Found Medical Education & Res Methods and materials for gender-dependent treatment of cardiovascular dysfunction
EP4011873A1 (en) 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3437917A1 (en) * 1984-10-17 1986-04-17 Bayer Ag, 5090 Leverkusen COMBINATION OF DIHYDROPYRIDINE WITH ACE INHIBITORS AND THEIR USE IN MEDICINAL PRODUCTS
TW197945B (en) * 1990-11-27 1993-01-11 Hoechst Ag
DE4308504A1 (en) * 1993-03-18 1994-09-22 Knoll Ag New use of a combination of verapamil and trandolapril
US5973011A (en) * 1994-03-30 1999-10-26 Isis Pharma Gmbh Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction
WO2000002851A1 (en) * 1998-07-08 2000-01-20 Aventis Pharma Deutschland Gmbh Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
EP1235563A2 (en) * 1998-08-26 2002-09-04 Queen's University At Kingston Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
WO2002034248A2 (en) * 2000-10-20 2002-05-02 Boehringer Ingelheim Pharmaceuticals, Inc. METHOD FOR INCREASING TISSUE PERFUSION BY CO-ADMINISTRATION OF AN AGENT THAT INCREASES cGMP SYNTHESIS AND AN AGENT THAT INHIBITS cGMP DEGRADATION
US20050181066A1 (en) * 2002-04-26 2005-08-18 Altana Pharma Ag Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency
JP2005529927A (en) * 2002-05-23 2005-10-06 ファイザー インコーポレイテッド New combination

Also Published As

Publication number Publication date
GB0318094D0 (en) 2003-09-03
WO2005011727A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
WO2003059296A3 (en) Compositions comprising collagen and metalloprotease inhibitors
TW200517145A (en) Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
MXPA05006629A (en) Dosage forms containing a proton pump inhibitor, a nsaid, and a buffer.
WO2004018431A3 (en) Novel phenanthridines
MY127495A (en) Dipeptide derivatives
DE59911670D1 (en) Glutamine thiazolidides and pyrrolidides and their use as dipeptidyl peptidase IV inhibitors
ATE287402T1 (en) NANOMOLAR, NON-PEPTIDIC INHIBITORS OF CATHEPSIN D
MY138732A (en) Conjugated complement cascade inhibitors
AU2003291356A1 (en) Methods and compositions for treating cancer using proteasome inhibitors
MXPA03006224A (en) Inhibitors of cruzipain and other cysteine proteases.
TW200509911A (en) Novel combination
AU2001264065A1 (en) Serine protease inhibitors
MXPA05006368A (en) Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2.
MXPA02012713A (en) A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES.
MY133625A (en) Peptide deformylase inhibitors
AU2001264081A1 (en) Serine protease inhibitors
SI1511718T1 (en) N-acylaminobenzene dervatives as selective monoamine oxidase b inhibitors
TW200508233A (en) Chk-1 inhibitors
WO2005053725A3 (en) Cancer treatment
WO2003099194A3 (en) Pharmaceutical combination of pde5 inhibitors with ace inhibitors
WO2005042022A3 (en) Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist
MXPA05011783A (en) Peptides having an ace inhibiting effect.
AP2003002855A0 (en) Inhibitor of monoamine uptake.
AU2003223634A1 (en) Peptide deformylase inhibitors
TW200510276A (en) Calcilytic compounds